Targets › TNFSF14
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Cytokine that binds to TNFRSF3/LTB and TNFRSF14/HVEM and plays major roles in immune system regulation. Upon binding to TNFRSF14/HVEM, delivers costimulatory signals to T cells, leading to T cell proliferation and IFNG production. (UniProt, O43557)
Open in Phaseline: the race on TNFSF14, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Englumafusp alfa CD19-targeted 4-1BB ligand | CD19, TNFSF14 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.